Navigation Links
Enox Biopharma, Inc. Will Present at IN360 Investment in Innovation Conference
Date:3/1/2012

VANCOUVER, British Columbia, March 1, 2012 /PRNewswire/ -- Enox Biopharma, Inc. (VANCOUVER, BC.) CEO, John C. Rewcastle, Ph.D., will present at the IN360 Investment in Innovation Conference on Thursday, March 1 at 10:35 AM EST. The conference is being held at the Ritz Carlton Hotel in Orlando.

The IN360 is the newest iteration of the successful IN3 meeting series, hosted by Elsevier. It is a medical device technology forum and networking meeting. The foundation of the meeting is presentations from emerging companies like Enox Biopharma to audiences principally composed of larger medical device manufacturers and venture capitalists.

Dr. Rewcastle will present Enox's technology whose foundation is the patent protected ability to embed nitric oxide into polymers which renders medical devices antimicrobial. This innovative technology is a potential solution to one of the most significant burdens on medical systems worldwide: hospital acquired infections.

"In the United States alone, it is estimated that $30-45 billion dollars per year are spent due to hospital acquired infections," said Enox CEO John Rewcastle. "Enox is uniquely positioned to address this problem by inhibiting the formation of infections seeded when a medical device such as a catheter is inserted into the body. With nitric oxide as the mechanism of action, devices incorporating our technology will not have issues such as non-effectiveness or antibiotic resistance as do competitive products."

"The IN360 meeting is a uniquely effective environment provide exposure and constructive interaction between emerging and established medical device companies," continued Rewcastle. "Enox will be especially attractive to potential strategic partners in attendance. Our breakthrough technology has the potential of meeting the needs of hospitals worldwide who are currently underserved by existing infection prevention technology."

About Enox Biopharma, Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into polymers. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. NO is also an effective vasodilator which can lead to accelerated wound healing. Enox's device technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes and central venous catheters. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide.

For more information, please contact:

John C. Rewcastle, Ph.D, CEO or
Itamar David, CFO
Enox Biopharma, Inc.
604.637.9744 phone

888.224.7259 fax
info@enoxbiopharma.com
www.enoxbiopharma.com


'/>"/>
SOURCE Enox Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Enox Biopharma, Inc. Expands Its Technology to Cover the Wound Care Market
2. PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015
3. Enox Biopharma, Inc. Appoints Dr. John Rewcastle as CEO
4. Sinobiopharma, Inc. Appoints New Director of Marketing
5. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
6. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
7. Regeneron Announces March 2012 Investor Conference Presentations
8. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
9. OncoSec to Present at 10th Annual BioPartnering North America
10. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
11. Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... 12, 2017 , ... Huffman Engineering, Inc. , a leader in control ... the company’s Lincoln office as a chemical engineer. In his new role, Beck ... in the life science manufacturing and water/wastewater industries. , Prior to joining Huffman Engineering, ...
(Date:1/12/2017)... 2017 The report "Direct-Fed Microbials Market by Type (Lactic Acid Bacteria ... and Region - Global Forecast to 2022", published by MarketsandMarkets, the global market ... to reach USD 1,399.6 Million by 2022, at a CAGR of 6.96% from ... ... MarketsandMarkets Logo ...
(Date:1/11/2017)... BELLINGHAM, Washington, USA (PRWEB) , ... January 11, ... ... SPIE, the international society for optics and photonics , are commending the ... and photonics, following the signing Friday by the President of the American Innovation ...
(Date:1/11/2017)... ... January 11, 2017 , ... IsoPlexis ... response analysis platform to measure the proteomic function of individual cells in patients, ... Research (SBIR) grant from the National Institute on Aging of the National Institutes ...
Breaking Biology Technology:
(Date:1/6/2017)... 6, 2017  Privately-held CalciMedica, Inc., announced that ... volunteers of a novel calcium release-activated calcium (CRAC) ... Acute pancreatitis, sudden painful inflammation ... but can be very serious.  In severe cases it ... extended hospital stays, time in the ICU and ...
(Date:1/6/2017)... 5, 2017  Delta ID Inc., a leader in ... for automotive at CES® 2017. Delta ID has collaborated ... demonstrate the use of iris scanning as a secure, ... driver in a car, and as a way to ... Delta ID and Gentex will demonstrate (booth ...
(Date:1/4/2017)... VEGAS , Jan. 4, 2017  CES ... performance biometric sensor technology, today announced the launch ... sensor systems, the highly-accurate biometric sensor modules ... biometric technology, experience and expertise. The two ... Benchmark designed specifically for hearables, and Benchmark BW2.0, ...
Breaking Biology News(10 mins):